Gene · 6607
Papers3,510
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
481 to 500 of 3,510
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| PROCEEDINGS OF THE XXIII CONGRESS OF THE ITALIAN ASSOCIATION OF MYOLOGY: PadovaJune 8-10, 2023. | Acta Myol | 2023 | 37650038 | PubTator, text mining | PubMed |
| Diagnostic implications of pitfalls in causal variant identification based on 4577 molecularly characterized families. | Nat Commun | 2023 | 37644014 | PubTator, text mining | PubMed |
| Progress on RNA-based therapeutics for genetic diseases. | Zhejiang Da Xue Xue Bao Yi Xue Ban | 2023 | 37643975 | PubTator, text mining | PubMed |
| Danon Disease: Entire LAMP2 Gene Deletion with Unusual Clinical Presentation-Case Report and Review of the Literature. | Genes (Basel) | 2023 | 37628591 | PubTator, text mining | PubMed |
| Progress and Prospects of Gene Editing in Pluripotent Stem Cells. | Biomedicines | 2023 | 37626665 | PubTator, text mining | PubMed |
| Spinal Muscular Atrophy Type I With False Negative in Newborn Screening: A Case Report. | Cureus | 2023 | 37621829 | PubTator, text mining | PubMed |
| Childhood spinal muscular atrophy. | Handb Clin Neurol | 2023 | 37620083 | PubTator, text mining | PubMed |
| Photoswitchable molecular glue for RNA: reversible photocontrol of structure and function of the ribozyme. | Nucleic Acids Res | 2023 | 37615580 | PubTator, text mining | PubMed |
| Using deep long-read RNAseq in Alzheimer's disease brain to assess medical relevance of RNA isoform diversity. | bioRxiv | 2023 | 37609156 | PubTator, text mining | PubMed |
| Alberta Spinal Muscular Atrophy Newborn Screening-Results from Year 1 Pilot Project. | Int J Neonatal Screen | 2023 | 37606479 | PubTator, text mining | PubMed |
| Health Care Resource Utilization and Costs for Patients with Spinal Muscular Atrophy: Findings from a Retrospective US Claims Database Analysis. | Adv Ther | 2023 | 37587305 | PubTator, text mining | PubMed |
| Pan-Cancer Profiling and Digital Pathology Analysis Reveal Negative Prognostic Biomarker ZPR1 Associated with Immune Infiltration and Treatment Response in Hepatocellular Carcinoma. | J Hepatocell Carcinoma | 2023 | 37581094 | PubTator, text mining | PubMed |
| Epidemiology of spinal muscular atrophy caused by SMN1 deletions in Maritime Canada. | Am J Med Genet A | 2023 | 37578329 | PubTator, text mining | PubMed |
| Spinal Muscular Atrophy: The Past, Present, and Future of Diagnosis and Treatment. | Int J Mol Sci | 2023 | 37569314 | PubTator, text mining | PubMed |
| Molecular Biomarkers for the Diagnosis, Prognosis, and Pharmacodynamics of Spinal Muscular Atrophy. | J Clin Med | 2023 | 37568462 | PubTator, text mining | PubMed |
| Nusinersen Treatment of Children with Later-Onset Spinal Muscular Atrophy and Scoliosis Is Associated with Improvements or Stabilization of Motor Function. | J Clin Med | 2023 | 37568304 | PubTator, text mining | PubMed |
| Studies of Genetic and Proteomic Risk Factors of Amyotrophic Lateral Sclerosis Inspire Biomarker Development and Gene Therapy. | Cells | 2023 | 37566027 | PubTator, text mining | PubMed |
| Feasibility and tolerability of multimodal peripheral electrophysiological techniques in a cohort of patients with spinal muscular atrophy. | Clin Neurophysiol Pract | 2023 | 37554725 | PubTator, text mining | PubMed |
| APOE loss-of-function variants: Compatible with longevity and associated with resistance to Alzheimer's Disease pathology. | medRxiv | 2023 | 37547016 | PubTator, text mining | PubMed |
| Multi-omics profiling of CSF from spinal muscular atrophy type 3 patients after nusinersen treatment: a 2-year follow-up multicenter retrospective study. | Cell Mol Life Sci | 2023 | 37543540 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/6607/papers?page=25